TX-FLUENCE
19.10.2021 15:02:06 CEST | Business Wire | Press release
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today it will debut products at MJBizCon 2021, including its high-output SPYDR 2h, SPYDR Fang, waterproof RAZR Enclosed and next-generation RAPTR top light as well as its new lighting controls, Wireless Flex Dimming and the SHYFT Light Scheduler.
Following the announcement of its multiyear global research study results —which showcased the effects of broad-spectrum lighting solutions on crop yield and quality—Fluence will demo its innovative new products at the company’s MJBizCon booth, located at No. C3515.
“In our recently announced research results, Fluence noted a clear, positive impact on cannabis crop yield, cannabinoid content and overall plant quality under broad-spectrum lighting,” said David Cohen, CEO of Fluence. “According to the 2021 State of the Cannabis Lighting Market report , LED usage for cannabis cultivation has increased more than 45 percent for all stages of growth since the initial report in 2016. The efficacy of LED lighting solutions for cannabis cultivation is no longer a question. Cultivators have embraced the power of LEDs and are seeking new ways to harness broad-spectrum lighting technology to optimize their cultivation environments. Fluence’s innovative new products—informed by the latest photobiology research—will enable cultivators to achieve exceptional crop performance.”
The latest luminaires from Fluence include:
- SPYDR 2h: An extension of Fluence’s SPYDR series—featuring luminaires designed for single- or multitier growers who want to optimize grow space—the company’s high-output SPYDR 2h produces a photosynthetic photon flux of up to 2,080 μmol/s. Supported by results from Fluence’s multiyear global research studies observing cannabis growth under high light intensities, the SPYDR 2h is designed to maximize yields.
- SPYDR Fang: The SPYDR Fang is designed specifically for the retail buyer and built with Fluence’s trusted, research-backed and science-led engineering leveraged by commercial growers throughout the world.
- RAZR Enclosed: Following its debut in June 2021, the RAZR Modular System is now IP67 waterproof to withstand hyper-wet and humid environments within a vertical farm. The RAZR series is also now available with various spectral options, including broad-white as well as dual red and blue light. Fluence will showcase the system’s newest features through video at the company’s MJBizCon booth.
- RAPTR: Fluence’s latest top light solution serves as an advanced one-to-one high-pressure sodium replacement. The next-generation top light consumes 1,000 watts at a high output, plugging in seamlessly to a grower’s existing facility for streamlined retrofits.
“Fluence’s high-output SPYDR 2h will transform how cannabis cultivators approach each stage of plant production,” said Jordon Musser, chief product officer for Fluence. “We’ve seen incredible yield and quality metrics at high PPFDs and we’re excited to collaborate with our growers to incorporate high-intensity lighting and cultivation strategies into their operations.”
The company will also debut its innovative lighting controls, including:
- SHYFT: Available in North America, Fluence’s light scheduler, SHYFT, offers patented photoacclimation capability and daily photoperiod control for 0 to 10 V LED and dimmable fluorescent fixtures. At MJBizCon, visit the Fluence booth to see SHYFT control each of the company’s luminaires and witness its advanced lighting control capabilities.
- Wireless Flex Dimming: In addition to SHYFT, Fluence’s Wireless Flex Dimming solution leverages Bluetooth mesh technology to wirelessly control fixtures. With Wireless Flex Dimming’s plug-and-play design, growers gain increased flexibility over light levels with no wire installations or additional labor costs. Fluence team members will demo the product’s wireless capabilities from within the booth.
“MJBizCon is the world’s stage for unveiling leading cannabis innovations and we’re thrilled to debut multiple solutions that are advancing the global cannabis market forward,” said Lorrie Schultz, senior vice president of marketing for Fluence. “We’re eager to showcase our new products at MJBizCon and exemplify how Fluence is helping cannabis cultivators grow smarter.”
For more information on Fluence, its products and release dates for the company’s newest solutions, visit the team at MJBizCon from Oct. 20, 2021 to Oct. 22, 2021 at booth No. C3515 or explore Fluence’s website at www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20211019005390/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom